- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00003917
Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer
An Open Label, Multicenter, Randomized, Phase III Comparator Study of Oral Topotecan Versus Intravenous Topotecan for Second Line Therapy in Patients With Small Cell Lung Cancer Who Have Relapsed Greater Than or Equal to 90 Days After Completion of First Line Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if topotecan is more effective given by infusion or by mouth.
PURPOSE: Randomized phase III trial to compare the effectiveness of topotecan given by infusion with that of topotecan given by mouth in treating patients who have small cell lung cancer that has relapsed following previous therapy.
Panoramica dello studio
Descrizione dettagliata
OBJECTIVES: I. Compare the response rate, response duration, time to response, time to progression, and survival of patients with relapsed limited or extensive stage small cell lung cancer treated with oral vs intravenous topotecan. II. Compare the qualitative and quantitative toxicities of these treatment regimens in this patient population. III. Compare the quality of life in these patients.
OUTLINE: This is randomized, multicenter study. Patients are stratified according to gender, liver metastases (yes vs no), and duration of response to prior chemotherapy (6 months or less vs greater than 6 months). Patients are randomized to one of two treatment arms. Arm I: Patients receive topotecan IV over 30 minutes on days 1-5. Arm II: Patients receive topotecan orally on days 1-5. Treatment repeats every 3 weeks in the absence of unacceptable toxicity. Patients experiencing complete or partial response continue until progression or for at least 2 courses past maximal response. Patients with stable disease should receive at least 4 courses. Quality of life is assessed Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 300 patients (150 per treatment arm) will be accrued for this study.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35294
- University of Alabama Comprehensive Cancer Center
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85012
- Veterans Affairs Medical Center - Phoenix (Hayden)
-
-
California
-
Bakersfield, California, Stati Uniti, 93309
- Comprehensive Blood and Cancer Center
-
Fountain Valley, California, Stati Uniti, 92708
- Pacific Coast Hematology/Oncology Medical Group
-
La Jolla, California, Stati Uniti, 92037
- Scripps Clinic
-
Los Angeles, California, Stati Uniti, 90073
- Veterans Affairs Medical Center - West Los Angeles
-
Poway, California, Stati Uniti, 92064
- Southwest Cancer Care
-
Sacramento, California, Stati Uniti, 95817
- University of California Davis Cancer Center
-
San Diego, California, Stati Uniti, 92120
- Kaiser Permanente-Southern California Permanente Medical Group
-
San Diego, California, Stati Uniti, 92121
- Sidney Kimmel Cancer Center
-
-
Colorado
-
Colorado Springs, Colorado, Stati Uniti, 80909
- Oncology Clinic, P.C.
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32610
- Shands Cancer Center
-
Jacksonville, Florida, Stati Uniti, 32207
- Baptist Regional Cancer Institute - Jacksonville
-
Miami, Florida, Stati Uniti, 33176
- Oncology-Hematology Group of South Florida
-
Pensacola, Florida, Stati Uniti, 32522
- Baptist Hospital- Pensacola
-
Tampa, Florida, Stati Uniti, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Augusta, Georgia, Stati Uniti, 30912-3620
- Medical College of Georgia Hospital and Clinics
-
-
Illinois
-
Evanston, Illinois, Stati Uniti, 60201
- Evanston Northwestern Health Care
-
Hines, Illinois, Stati Uniti, 60141
- Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46219
- Oncology and Hematology Associates, Inc.
-
-
Louisiana
-
Lafayette, Louisiana, Stati Uniti, 70506
- Louisiana Oncology Associates
-
New Orleans, Louisiana, Stati Uniti, 70121
- Alton Ochsner Medical Foundation Hospital
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Hospital
-
Pontiac, Michigan, Stati Uniti, 48341-2985
- St. Joseph Mercy Hospital
-
-
Minnesota
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- CCOP - Metro-Minnesota
-
-
Missouri
-
Saint Louis, Missouri, Stati Uniti, 63141
- St. John's Mercy Medical Center
-
-
New Jersey
-
Camden, New Jersey, Stati Uniti, 08103
- Cooper Cancer Institute
-
Livingston, New Jersey, Stati Uniti, 07039
- St. Barnabas Medical Center
-
Voorhees, New Jersey, Stati Uniti, 08043
- Cooper Hospital/University Medical Center
-
-
New Mexico
-
Santa Fe, New Mexico, Stati Uniti, 87505
- Santa Fe Hematology/Oncology
-
-
New York
-
Rochester, New York, Stati Uniti, 14621
- Rochester General Hospital
-
Syracuse, New York, Stati Uniti, 13210
- State University of New York - Upstate Medical University
-
-
North Carolina
-
Winston-Salem, North Carolina, Stati Uniti, 27157-1082
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
-
Winston-Salem, North Carolina, Stati Uniti, 27103
- Salem Research
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106-5065
- Ireland Cancer Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Penn State Geisinger Cancer Center
-
Lemoyne, Pennsylvania, Stati Uniti, 17043-1440
- Central Pennsylvania Hematology & Medical Oncology Associates, PC
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- University of Pittsburgh Cancer Institute
-
Reading, Pennsylvania, Stati Uniti, 19612-6052
- Reading Hospital and Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02912
- Brown University Oncology Group
-
-
South Carolina
-
Greenville, South Carolina, Stati Uniti, 29605
- Cancer Centers of the Carolinas
-
Spartanburg, South Carolina, Stati Uniti, 29303
- Spartanburg Regional Healthcare System
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37901
- Baptist Regional Cancer Center - Knoxville
-
Nashville, Tennessee, Stati Uniti, 37203
- Sarah Cannon-Minnie Pearl Cancer Center
-
-
Texas
-
Fort Worth, Texas, Stati Uniti, 76104
- Texas Cancer Care
-
Galveston, Texas, Stati Uniti, 77555-0209
- University of Texas Medical Branch
-
Houston, Texas, Stati Uniti, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
Lubbock, Texas, Stati Uniti, 79410
- Joe Arrington Cancer Center
-
Temple, Texas, Stati Uniti, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Norfolk, Virginia, Stati Uniti, 23502
- Office of Michael E. Lee
-
Richmond, Virginia, Stati Uniti, 23226
- Hematology & Oncology Associates of Virginia
-
Roanoke, Virginia, Stati Uniti, 24014
- Oncology and Hematology Associates of Southwest Virginia, Inc.
-
-
Wisconsin
-
Waukesha, Wisconsin, Stati Uniti, 53188
- Waukesha Memorial Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed limited or extensive stage small cell lung cancer (SCLC) Disease recurring at least 90 days following completion of first line chemotherapy Partial or complete response to first line therapy Must have at least one bidimensionally measurable non CNS lesion May be within a prior radiation port if at least 6 weeks since prior radiotherapy and progressing Brain and/or leptomeningeal metastases allowed if asymptomatic and not requiring corticosteroids
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 2 months Hematopoietic: WBC at least 3,500/mm3 Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL (after transfusion, if needed) Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT and SGPT no greater than 2 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present) Alkaline phosphatase no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present) Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Other: No active uncontrolled infection No other malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I low grade prostate cancer No other severe medical conditions that would preclude study or cause exposure to extreme risk or decreased life expectancy No uncontrolled emesis No active peptic ulcer, diabetes mellitus, chronic gastritis, significant ascites, or other gastrointestinal (GI) conditions (e.g., removal of a portion of the stomach or recent GI obstruction) that would alter absorption or GI motility No history of allergic reactions to compounds chemically related to topotecan Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception for 3 months prior to, during, and at least 4 weeks after the study
PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 months since prior immunotherapy No concurrent immunotherapy for SCLC Chemotherapy: See Disease Characteristics No prior topotecan Only one prior chemotherapy regimen allowed No other concurrent chemotherapy for SCLC Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics At least 24 hours since prior radiotherapy No concurrent radiotherapy for SCLC Surgery: At least 4 weeks since prior surgery Other: At least 30 days or five half lives since other prior investigational drugs No prior drugs (e.g., cisapride) that would alter absorption or GI motility No other concurrent investigational therapy for SCLC
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Cattedra di studio: Nathan Levitan, MD, Case Comprehensive Cancer Center
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie delle vie respiratorie
- Neoplasie
- Malattie polmonari
- Neoplasie per sede
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Neoplasie polmonari
- Carcinoma polmonare a piccole cellule
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Inibitori della topoisomerasi
- Inibitori della topoisomerasi I
- Topotecan
Altri numeri di identificazione dello studio
- SKF1598
- CWRU-SKF-1598
- SB-104864-A/396
- NCI-G99-1524
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro ai polmoni
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Attivo, non reclutanteStadio III Adenocarcinoma della prostata AJCC v7 | Stadio II Adenocarcinoma prostatico AJCC v7 | Fase I Adenocarcinoma della prostata American Joint Committee on Cancer (AJCC) v7Stati Uniti
Prove cliniche su topotecan cloridrato
-
Targeted Therapy Technologies, LLCAttivo, non reclutante
-
The Hospital for Sick ChildrenReclutamentoRetinoblastomaCanada
-
Gustave Roussy, Cancer Campus, Grand ParisErasmus Medical Center; Catholic University of the Sacred Heart; St. Anna KinderkrebsforschungCompletatoNeuroblastoma | Tumori solidi | Tumori cerebraliFrancia
-
Hospital JP GarrahanHospital San Juan de Dios, SantiagoAttivo, non reclutanteRetinoblastoma unilateraleArgentina
-
GlaxoSmithKlineCompletato
-
GlaxoSmithKlineCompletatoTumore endometriale | Neoplasie, endometrioStati Uniti, Canada, Ungheria
-
Gachon University Gil Medical CenterSconosciutoCancro ai polmoni | Refrattaria alla chemioterapiaCorea, Repubblica di
-
GlaxoSmithKlineCompletatoCancro polmonare, piccola cellulaStati Uniti, Olanda
-
GlaxoSmithKlineCompletatoCancro polmonare, piccola cellulaBulgaria, Ungheria, Federazione Russa, Olanda, Ucraina, Regno Unito
-
National Cancer Institute (NCI)CompletatoCarcinoma polmonare a piccole cellule ricorrenteStati Uniti, Singapore